Intravenous iron and SGLT2 inhibitors in iron‐deficient patients with heart failure and reduced ejection fraction

Abstract

Abstract Aims To explore the potential interaction between use of SGLT2 inhibitors and the increase in haemoglobin in patients randomized to intravenous iron or the control group in the IRONMAN (Effectiveness of Intravenous Iron Treatment versus Standard Care in Patients with Heart Failure and Iron Deficiency) trial. Methods and results This was a post hoc exploratory analysis of the IRONMAN trial which randomized patients with heart failure, a left ventricular ejection fraction (LVEF) ≤ 45% and iron deficiency (transferrin saturation 16.5 g/dL [men] or >16 g/dL [women]). Conclusions In the IRONMAN trial, there was a trend to a greater increase in haemoglobin with ferric derisomaltose in iron‐deficient patients taking an SGLT2 inhibitor at baseline, as compared with those not taking one.

Keywords

• Chronic heart failure
• Intravenous iron
• Iron deficiency
• SGLT2 inhibitor